Evidence map›Paper›PMID 39587544›Full record

SynthesisLipids in health and disease2024

Serum lipid profile abnormalities among beta-thalassemia patients: a systematic review and meta-analysis.

Sagad O O Mohamed, Ali E A Mohamed, Mohamed S K Salih, Khalid S K Salih, Ahmed S E E Abdelrahman, Ahmed G A Abdelgadir, Mona G A Ahmedkaroum, Gehad A Abdalla, Hanaa A M Fadil, Mahmoud A M Abdelrahman and 1 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Lipids in health and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sagad O O MohamedFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan. s.oom123@yahoo.com.
Ali E A MohamedFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Mohamed S K SalihHarlem Hospital Center, New York, NY, US.
Khalid S K SalihUnited Lincolnshire Hospitals Trust, Lincolnshire, UK.
Ahmed S E E AbdelrahmanFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Ahmed G A AbdelgadirFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Mona G A AhmedkaroumFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Gehad A AbdallaFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Hanaa A M FadilFaculty of Medicine, University of Khartoum, P.O. Box 302, Khartoum, Sudan.
Mahmoud A M AbdelrahmanFaculty of Medicine, Nile University, Khartoum, Sudan.
Nehal S A SalihFaculty of Medicine, University of Bahri, Khartoum, Sudan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with betathalassemia have higher risk of various metabolic disturbances. The literature presents conflicting results about the patterns of abnormal lipid profile among patients with betathalassemia. This systematic review aimed to assess dyslipidemia patterns among patients with betathalassemia when compared with healthy individuals.

methodsThe methods used were adherent to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. Systematic searches of the literature were done across Medline/PubMed, Web of Science, Science Direct, and Regional Portal of the World Health Organization Virtual Health Library. Calculation of standardized mean difference (SMD) estimates and their associated 95% confidence intervals (CIs) were done through Jamovi software.

resultsThe systematic review included 21 studies meeting the criteria for the analyses. Patients with beta-thalassemia major displayed significantly elevated triglyceride levels (SMD: 0.448, 95% CI, 0.214 to 0.682; P < .001) and reduced total serum cholesterol (SMD: -2.26 (95% CI-2.834 to -1.678; P < .001), as well as decreased levels of both low-density lipoprotein cholesterol (SMD: -1.88, 95% CI, -2.614 to -1.147; P < .001) and high-density lipoprotein cholesterol (SMD: -1.32, 95% CI, -1.786 to -0.860; P < .001). Similarly, beta-thalassemia intermedia patients exhibited comparable lipid profile abnormalities to those with beta-thalassemia major. Conversely, beta-thalassemia minor patients only showed significantly lower total serum cholesterol levels (SMD: -0.66, 95% CI, -0.860 to -0.472; P < .001).

conclusionEvidence indicates alterations in lipid profile markers among beta-thalassemia patients. The findings indicate the importance of assessing hypertriglyceridemia and hypocholesterolemia in these patients, especially those with major and intermedia forms, as these lipid profile abnormalities increase the risk of cardiovascular disease.

Indexed as

beta-ThalassemiaLipidsTriglyceridesCholesterolCholesterol, HDLCholesterol, LDLDyslipidemiasHumansCholesterolCholesterol, HDLCholesterol, LDLLipidsTriglyceridesBetathalassemiaCholesterolDyslipidemiaLipidsMeta-analysisTriglyceride

Identifiers

PMID39587544
PMCPMC11587755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.